http://purl.org/np/RAcnhAgYVf... RAcnhAgYVf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-06-28T06:53:08.231Z

http://purl.org/np/RAcnhAgYVf... RAcnhAgYVf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

pantoprazole sodium delayed release tablets are indicated for pantoprazole sodium delayed release tablet is a proton pump inhibitor indicated for the following short term treatment of erosive esophagitis associated with gastroesophageal reflux disease gerd 1 1 maintenance of healing of erosive esophagitis 1 2 pathological hypersecretory conditions including zollinger ellison syndrome 1 3 pantoprazole sodium delayed release tablets are indicated in adults for the short term treatment up to 8 weeks in the healing and symptomatic relief of erosive esophagitis for those adult patients who have not healed after 8 weeks of treatment an additional 8 week course of pantoprazole sodium delayed release tablets may be considered safety of treatment beyond 8 weeks in pediatric patients has not been established pediatric indication and usage information in pediatric patients ages five years and older with erosive esophagitis associated with gerd is approved for wyeth pharmaceuticals inc s pantoprazole sodium delayed release tablets however due to wyeth pharmaceuticals inc s marketing exclusivity rights this drug product is not labeled with that pediatric information pantoprazole sodium delayed release tablets are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd controlled studies did not extend beyond 12 months pantoprazole sodium delayed release tablets are indicated for the long term treatment of pathological hypersecretory conditions including zollinger ellison syndrome

Leoni Bücken

2021-06-28T06:53:08.231Z

http://purl.org/np/RAcnhAgYVf... RAcnhAgYVf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_8534 DOID_8534

Leoni Bücken

2021-06-28T06:53:08.231Z

http://purl.org/np/RAcnhAgYVf... RAcnhAgYVf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-06-28T06:53:08.231Z

http://purl.org/np/RAcnhAgYVf... RAcnhAgYVf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB00213 drugbank:DB00213

Leoni Bücken

2021-06-28T06:53:08.231Z

http://purl.org/np/RAcnhAgYVf... RAcnhAgYVf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-06-28T06:53:08.231Z

http://purl.org/np/RAcnhAgYVf... RAcnhAgYVf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-06-28T06:53:08.231Z

http://purl.org/np/RAcnhAgYVf... RAcnhAgYVf

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://w3id.org/um/neurodkg/SymptomaticReliefIndication SymptomaticReliefIndication

Leoni Bücken

2021-06-28T06:53:08.231Z